Rosetta, Abbott, Monsanto deal

RSTA and ABT will use animal and human liver model systems to study the molecular basis of toxicity for a range of compounds and develop a database of the information. The companies will use RSTA's FlexJet DNA microarray technology and Resolver gene expression data analysis software to determine gene expression profiles of toxic compounds, and will develop algorithms to predict compound toxicity in humans using expression profile data from the model systems. Each company will fund its own contributions to the project. ...